Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 31 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Kefkowitz M, Starling R, Teerlink J, McMurray JJV, Solomon SD, for the PARADIGM-HF Investigators. Influenze of sacubitril/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. J Am Coll Cardiol 2016;68:1-8. [Ref.ID 100489]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJS, Cleland JGF, Kirchhof P, von Lueder TG, Rigby AS, Andersson B, Lip GYH, van Veldhuisen DJ, Shibata MC, Wedel H, Böhm M, Flather MD, on behalf of the Beta-Blockers in Heart Failure Collaborative Group. Effect of age and sex on efficacy and tolerability of ß blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ 2016;352:i1855. [Ref.ID 100194]
3.Tiene citas relacionadas Cita con resumen
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, for the PARADIGM-HF Investigators and Committees. Angiotensin - Neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. [Ref.ID 98476]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Jessup M, Komajda FM, McMurray JJV, Packer M. Perspective roundtable: PARADIGM-HF - The experts' discussion. N Engl J Med 2014;371:e15. [Ref.ID 98475]
5. Cita con resumen
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, for the PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. [Ref.ID 98005]
6. Cita con resumen
Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber F-X, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M, for the SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007;297:1883-91. [Ref.ID 79575]
7.Tiene citas relacionadas Cita con resumen
Krum H, Roecker E B, Mohacsi P, Rouleau J L, Tendera M, Coats AJS, Katus HA, Fowler MB, Packer M, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure. Results from the COPERNICUS study. JAMA 2003;289:712-8. [Ref.ID 65026]
8.Tiene citas relacionadas
Packer M, Roecker E B. Effects of beta-blocker therapy in severe chronic heart failure. The authors reply. N Engl J Med 2001;345:998-9. [Ref.ID 58711]
9.Tiene citas relacionadas Cita con resumen
Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau J L, Tendera M, Castaigne A, Roecker E B, Schultz MK, DeMets DL, for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8. [Ref.ID 56682]
10.Tiene citas relacionadas Cita con resumen
Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow M R, Cohn JN, Lukas MA, Young ST, Packer M, for the U.S. Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358-65. [Ref.ID 56295]
11. Cita con resumen
Packer M, Poole-Wilson P A, Armstrong PW, et al on behalf of the A T L A S Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 2000;100:2312-8. [Ref.ID 52243]
12. Cita con resumen
Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of ß-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91. [Ref.ID 41007]
13.Tiene citas relacionadas
Packer M. Treatment of chronic heart failure. Lancet 1993;1:5-8. [Ref.ID 35254]
14.Tiene citas relacionadas
Packer M. Pathophysiology of chronic heart failure. Lancet 1993;I:1-5. [Ref.ID 35253]
15.Tiene citas relacionadas
Gilbert EM, Packer M. The use of placebo controls. N Engl J Med 1995;332:61. [Ref.ID 33794]
16.Tiene citas relacionadas
Packer M. Digoxin in patients with heart failure. The authors reply. N Engl J Med 1997;337:130. [Ref.ID 33456]
18.Tiene citas relacionadas
Packer M, Cohn JN, Colucci WS. Carvedilol in patients with chronic heart failure. N Engl J Med 1996;335:1319-20. [Ref.ID 29522]
19. Cita con resumen
Packer M, O'Connor CM, Ghali JK, Pressler M L, Carson PE, Belkin RN, Miller AB, Neuberg G W, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14. [Ref.ID 29275]
20.Tiene citas relacionadas Cita con resumen
Packer M, Bristow M R, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55. [Ref.ID 26870]
Seleccionar todas
 
 1 a 20 de 31 siguiente >>